Edition:
United States

Biofrontera AG (B8FGn.F)

B8FGn.F on Frankfurt Stock Exchange

2.92EUR
8:49am EDT
Change (% chg)

€-0.00 (-0.14%)
Prev Close
€2.92
Open
€2.86
Day's High
€2.96
Day's Low
€2.86
Volume
2,531
Avg. Vol
13,528
52-wk High
€4.18
52-wk Low
€1.58

B8FGn.F

Chart for B8FGn.F

About

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and... (more)

Overall

Beta: 0.43
Market Cap(Mil.): €89.07
Shares Outstanding(Mil.): 30.35
Dividend: --
Yield (%): --

Financials

  B8FGn.F Industry Sector
P/E (TTM): -- 43.70 36.51
EPS (TTM): -0.28 -- --
ROI: -131.79 -0.32 13.85
ROE: -- -3.00 14.77

BRIEF-Biofrontera completes patient recruitment of phase III trial of Ameluz in combination with Daylight-PDT

* Biofrontera completes patient recruitment of phase III trial of Ameluz in combination with Daylight-PDT

Sep 19 2016

BRIEF-Biofrontera receives label expansion for Ameluz in Europe

* Receives label expansion for Ameluz in Europe to include field cancerization

Sep 16 2016

BRIEF-Biofrontera H1 sales up 9 pct at 1.709 million euros

* Sales increased 9 pct to 1.709 million euros ($1.90 million)in H1 2016 compared to 1.568 million euros in H1 2015

Aug 31 2016

BRIEF-Biofrontera accelerates production of BF-Rhodoled lamps to prepare for U.S. commercial launch

* Accelerates production of BF-Rhodoled lamps to prepare for U.S. commercial launch

Aug 26 2016

BRIEF-Biofrontera gets favourable CHMP assessment for field-directed therapy

* Receives favourable CHMP assessment for field-directed therapy and files BCC application

Jul 28 2016

BRIEF-Biofrontera elects Ulrich Granzer as chairman of supervisory board

* On June 01 supervisory board elected Ulrich Granzer as chairman of supervisory board and Juergen Baumann as vice-chairman Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 02 2016

BRIEF-Biofrontera Q1 net loss before tax shrinks to EUR 0.4 mln

* Cash on balance sheet of 8.0 million euros ($8.92 million) as of March 31, 2016

May 25 2016

BRIEF-Biofrontera expects commercial launch of Ameluz and BF-RhodoLED in US by September 2016

* Expects commercial launch of Ameluz and BF-RhodoLED in U.S. by September 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 11 2016

BRIEF-Biofrontera: FDA grants approval for Ameluz in the USA

* Received unconditional FDA approval for marketing in the US for its prescription drug Ameluz in combination the PDT-lamp BF-RhodoLED for lesion-directed and field-directed treatment of mild to moderate actinic keratoses on face and the scalp

May 11 2016

BRIEF-Biofrontera FY 2015 total revenues up at 4.1 mln euros

* Reported FY total revenues of 4.1 million euros ($4.62 million)for full year, which represents a 34% increase year-over-year and was well within expectations

Apr 15 2016

Earnings vs. Estimates